Clinical Trials Logo
  1. Home
  2. Hepatorenal Syndrome
  3. NCT00089570

Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1

Hepatorenal Syndrome Clinical Trial

Official title:
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1

Clinical Trial Summary

The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00089570
Study type Interventional
Source Mallinckrodt
Contact
Status Completed
Phase Phase 3
Start date June 2004
Completion date September 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT00370253 - Noradrenalin vs Terlipressin in Hepatorenal Syndrome Phase 3
Completed NCT00359853 - Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Phase 4
Completed NCT01436500 - Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Phase 2
Completed NCT01143246 - A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Phase 3
Recruiting NCT05346393 - HRS-AKI Treatment With TIPS in Patients With Cirrhosis N/A
Terminated NCT00734136 - Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome N/A
Terminated NCT00742339 - Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome Phase 2/Phase 3
Recruiting NCT06095440 - A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
Completed NCT02097784 - Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury N/A
Recruiting NCT04898010 - The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I N/A
Recruiting NCT05875948 - Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome Phase 2
Completed NCT04416282 - Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure. N/A
Recruiting NCT02049125 - Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis N/A
Completed NCT00764049 - Single Pass Albumin Dialysis in Patients With Cirrhosis Phase 1/Phase 2
Withdrawn NCT01587222 - Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Phase 2
Recruiting NCT02489864 - The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Phase 4
Recruiting NCT02434445 - Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients N/A
Completed NCT02770716 - Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1 Phase 3
Completed NCT05387811 - International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
Withdrawn NCT04048707 - Angiotensin 2 for Hepatorenal Syndrome Phase 2